Lung Cancer Conference

Activity Overview

The clinical management of lung cancer is advancing at a rapid pace.  In particular, the identification of driver mutations and delineation of the molecular signature of lung cancers have resulted in significant improvements in the front-line treatment of both localized and advanced lung adenocarcinomas. ‘Molecular Therapeutics in Non-Small Cell Lung Cancer: A Virtual International Conference’ is a CME-accredited virtual conference which brings together the leading experts from around the world to discuss recent advances in the management of non-small cell lung cancer with a focus on biomarker-driven therapies, immuno-oncology, and clinical applications of the recent advances in non-small cell lung cancer, especially adenocarcinoma histology. This meeting will provide an opportunity to hear from the leading national and international experts on how recently published data would change practice, some of which will have immediate clinical applications. Furthermore, each session will have multiple segments on novel emerging treatment paradigms likely to transform the care of non-small cell lung cancers in the near future.

This virtual conference is intended to propagate new information to augment the knowledge and clinical competence of the cancer care providers in the following areas:

• Advances in the diagnosis & identification of molecular driver mutations
• Choice and sequencing of therapeutic options based on molecular mutation changes
• Use of molecular treatments in the adjuvant/curative setting
• Trends in the use of checkpoint inhibitors in curative and palliative therapy

Learning Objectives

Upon successful completion of this educational activity, participants will be able to:

• Explain the nuances of the use of plasma – vs – tissue-based molecular diagnostic testing
• Discuss recent data on the use of molecular targeted therapy in the adjuvant setting
• Summarize emerging data on the use of newly-available driver mutation testing and the targeted therapies available
• Review the newest data on the therapeutic uses of checkpoint inhibitor therapy.

Target Audience

This activity is directed toward medical oncologists who treat patients with lung cancer. Fellows, nurses, nurse practitioners, physician assistants, and other healthcare professionals involved in the management of lung cancer are also invited to participate.

Please visit our EDUCATION PORTAL to register for this conference.

Faculty

Dr. Joe Rosales

Virginia Mason Medical Center

Dr. Narjust Duma

University of Wisconsin

Dr. Tejas Patil

University of Colorado

Dr. Christina Baik

University of Washington & SCCA